Penny stocks are often regarded as one of the best ways for newbie investors to start their journey in the markets. Here is a look at four penny stocks that could be tracked by investors at the moment.
NNRF Inc. (OTC:NNRI): NNRF Inc. is structured in the form of a holding company and a leader in the green circular economy. It is focused on plasma-activated water (PAW) and zeolite technologies for developing sustainable products for a range of industries.
At the moment, the company operates through joint ventures and subsidiaries like NNPZ Pty Ltd., Zeolite Australia Pty Ltd., and Elevate Nutraceutics LLC. On August 3, the company announced the launch of www.nnrtinc.com, its official website. NNRF noted that the website was going to offer complete information about updates and resources with regards to the company’s ventures and subsidiaries in the PAW industry. The website offers an easy-to-navigate interface and easy access to detailed information about the diverse portfolio of NNRF.
In July, the company announced that it had appointed a new Director of Communications in the form of Taylor Pech. Pech boasts a strong academic pedigree, having attained Latin Honors in his Graduation and Phi Beta Kappa Honors from UCLA, which is one of the best universities in the world. Her linguistic flair and deep knowledge of Classical Civilization make her perfect for handling the diversity of corporate communications with aplomb.
Astra Energy Inc. (OTC:ASRE): The integrated solutions provider Astra Energy Inc. invests in and also develops clean and renewable energy projects where demand is high due to limited supply. Essentially, the company looks to address gaps in the market. On June 22, the company announced that its subsidiary, Astra Energy Tanzania Limited, had inked a Memorandum of Understanding with the Tanzania Electric Supply Company (TANESCO). The company would be involved in the development of a 350-megawatt combined-cycle power plant on the Tanzanian mainland.
TANESCO and Astra Energy had been working towards this agreement since March last year. At a meeting held at the United States Chamber of Commerce, the company first announced that it had been engaged in talks with the government of Tanzania. The aim of the discussions was to reach an agreement to build a large-scale combined-cycle power plant through the deployment of natural gas as the main source of fuel.
iQSTEL Inc. (OTC:IQST): iQSTEL Inc. has projected revenues of $105 million for the 2023 financial year, and the United States-based multinational company is making preparations for a NASDAQ listing. The company’s objective is to manufacture tools accessible across the world to everyone so as to serve the basic human needs of modern times. On July 12, the company announced that its revenues for the second fiscal quarter of 2023 surpassed expectations.
As per preliminary accounting, the company generated revenues of $32.5 million, which reflected a sequential rise of 32% from the previous quarter. The Chief Executive Officer of the company, Leandro Iglesias, noted that iQSTEL was on track to surpass its revenue forecast for the year. He went on to note that since the company had been launched in 2018, it had generated higher revenues in the second half of the year. Iglesias also stated that the organic growth of iQSTEL exceeded the management’s expectations.
Enzolytics Inc. (OTC:ENZC): The drug development company Enzolytics Inc. is focused on the commercialization of its proprietary proteins and monoclonal antibodies meant for the treatment of impairing infectious diseases. The company is involved in the advancement of a number of therapeutics meant to target a range of infectious diseases. On August 4, the company provided an update with regards to the permit application to the European Medicine Agency (EMA) for its patented ITV-1 immunotherapy for the treatment of HIV/AIDS.
The company revealed that the Bulgarian Academy of Science Institute of Organic Chemistry prepared a report with details about the module 3 clinical trials that would be conducted with the therapeutic. The report provided details about the research that would be performed, the process for pharmaceutical development of the therapeutic, a technical report about the production process, stability expectations, production control processes, characterization of impurities, and batch analysis guidelines.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.